Aripiprazole Tablet, Orally Disintegrating
Product Images NDC 72578-107

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Aripiprazole (NDC 72578-107). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Viona Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

F14d468d 36d9 4312 A2e8 E5993c0ab6ef 01

FDA Label Image

F14d468d 36d9 4312 A2e8 E5993c0ab6ef 02

This is a list of drugs and their effects on aripiprazole, an antipsychotic medication. The chart shows the fold change and 90% C relative to the reference (without interacting drug) for AUC, Cmax, and Ucmax. The drugs listed include a CYP3A4 inhibitor (ketoconazole), CYP2DS inhibitor (quinidine), CYP3A4 inducer (carbamazepine), gastric acid blocker (famotidine), valproate, lithium, and lorazepam.*

FDA Label Image

F14d468d 36d9 4312 A2e8 E5993c0ab6ef 03

This text appears to be a table listing the effects of different drugs on Aripiprazole, including inhibitors and inducers of certain enzymes, as well as specific drugs. The table includes measures such as AUC and Cmax, and also mentions "Dehydro-Aripiprazole Fold Change and 90% Cl." Without additional context, the purpose or implications of this information are not clear.*

FDA Label Image

F14d468d 36d9 4312 A2e8 E5993c0ab6ef 04

This text appears to be a table showing the effects of Aripiprazole, an antipsychotic drug, on the pharmacokinetics of other medications. It seems to be listing various drugs and their associated parameters, such as the area under the curve (AUC) and maximum concentration (Cmax), and how they are affected by Aripiprazole. The table also includes fold change values and confidence intervals for the drugs, although the meaning of these values is unclear without further context.*

FDA Label Image

F14d468d 36d9 4312 A2e8 E5993c0ab6ef 05

This appears to be a tabulated data with headings for different categories which include Special Populations, PK, CYP2D6, Gender, Age, Hepatic Impairment, Renal Impairment, and Aripiprazole Fold Change and 90% CI but without any actual values. It is likely a reference table for health professionals or research purposes related to pharmacokinetics and drug interactions. Therefore, a precise description cannot be provided without further information.*

FDA Label Image

F14d468d 36d9 4312 A2e8 E5993c0ab6ef 06

FDA Label Image

F14d468d 36d9 4312 A2e8 E5993c0ab6ef 07

This appears to be a chart comparing the effectiveness of two treatments, Aripiprazole and Placebo, for preventing relapse over a period of time. The chart shows the proportion of subjects who experienced relapse, as well as the number of subjects at risk. The data is broken down by day (in increments of 14 days) and by year (from 00-10). Aripiprazole appears to be more effective than Placebo in preventing relapse over time.*

FDA Label Image

F14d468d 36d9 4312 A2e8 E5993c0ab6ef 08

FDA Label Image

F14d468d 36d9 4312 A2e8 E5993c0ab6ef 09

The text represents a graph that compares the proportion of subjects with relapse taking aripiprazole and placebo over time. The graph shows that the proportion of subjects with relapse is lower for aripiprazole compared to placebo. The text also includes the number of subjects at risk and days from randomization. There is not enough information to provide a full description of the study or its results.*

FDA Label Image

F14d468d 36d9 4312 A2e8 E5993c0ab6ef 10

This text is describing a chart that shows the least-squares mean change in someone's YGTSS total TIC score. The change is measured from baseline and is shown for the treatment options of Abilify low, Abilify high, and placebo. The chart displays the measurement at weeks 1, 2, 4, 6, and 8 of treatment.*

FDA Label Image

F14d468d 36d9 4312 A2e8 E5993c0ab6ef 11

This is a description of a drug called Aripiprazole Orally Disintegrating Tablets, USP. It contains 10mg of Aripiprazole USP and is produced by Square Pharmaceuticals Ltd. It is distributed by Viona Pharmaceuticals Inc. and comes in a package of 30 tablets. The medication guide should be dispensed by the pharmacist to the patients. The drug should be stored in a tight container at a temperature of 20° to 25°C. The tablet contains 1.12 mg of phenyaanine, which is a component of aspartame. For complete prescribing information, the pharmacist should refer to the package insert. Children should not have access to this drug. Note: The text contains a lot of errors, which may affect the accuracy of the description.*

FDA Label Image

F14d468d 36d9 4312 A2e8 E5993c0ab6ef 12

The text provides information about a medication, Aripiprazole, which is distributed by Viona Pharmaceuticals Inc. The medication is in the form of orally disintegrating tablets with a strength of 15 mg. The package insert contains the complete prescribing information. The tablets contain phenylalanine and should be stored in a tight container at a controlled room temperature. The text also reminds to keep the medication out of the reach of children. The rest of the text is not-available as it consists of errors.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.